Ryan Murray, PhD’24, cut his own path to developing an emerging gene-edited cell therapy that could one day personalize treatment for disease. After completing his Industry PhD in Stephen Hatfield's lab, he co-founded KiraGen Bio. “I never thought I’d be an entrepreneur. I wanted to be in early science discovery, but through the LEADERs program I learned there’s other things you can do with your PhD that are still very scientifically focused in early-stage research,” says Murray, who worked at Northeastern University Center for Research Innovation (CRI). “You don’t have to be the one sitting there pipetting.” https://lnkd.in/eZRFFSEK Northeastern University. Northeastern University PhD Network. Fifty Years. #biotech #startup #entrepreneurship #industryphd #phdeducation #geneediting Northeastern University School of Pharmacy and Pharmaceutical Sciences.
The LEADERs Program at Northeastern University’s Post
More Relevant Posts
-
Ryan Murray, PhD’24, cut his own path to developing an emerging gene-edited cell therapy that could one day personalize treatment for disease. After completing his Industry PhD in Stephen Hatfield's lab, he co-founded KiraGen Bio. “I never thought I’d be an entrepreneur. I wanted to be in early science discovery, but through the LEADERs program I learned there’s other things you can do with your PhD that are still very scientifically focused in early-stage research,” says Murray, who worked at Northeastern University Center for Research Innovation (CRI). “You don’t have to be the one sitting there pipetting.” Click to read the full article. https://lnkd.in/eZRFFSEK Murray started KiraGen Bio with Aaron Edwards, who recently earned a dual degree from Harvard Business School and Harvard Kenneth C. Griffin Graduate School of Arts and Sciences. Northeastern University. The LEADERs Program at Northeastern University. Fifty Years. #biotech #startup #entrepreneurship #industryphd #phdeducation #geneediting Northeastern University School of Pharmacy and Pharmaceutical Sciences.
LEADERs Sets Industry PhD Student Ryan Murray, PhD’24, on a New Path to Entrepreneurship
https://phd.northeastern.edu
-
Get ready to be amazed by British Columbia's latest breakthroughs in Biotechnology! Check out our newest article featuring nine inspiring startups redefining the Biotech landscape in BC. Look into the story here: https://lnkd.in/gfGpyPEe You wouldn't want to miss the innovating work that these emerging startups are doing: 1. Avivo Biomedical Inc., pioneered by Geoff Houlton and John Barclay, innovating in cell surface antigens. 2. NanoVation Therapeutics™ Therapeutics, mastering nanotechnology for efficient delivery of nucleic acid tissues. 3. HAVN Life - Co-Founded by Alexzander Samuelsson 4. Rakovina Therapeutics, led by the brilliant minds of Jeffrey Bacha and Mads Daugaard 5. Levitee Labs, founded by Kelly Abbott spotlighting integrative wellness space. 6. Capsigen, initiated by Charlie Kang and John Bial, focusing on engineering novel AAV capsids. 7. Axolotl Biosciences, revolutionizing 3D printing in the Biotech industry. 8. BugSeq Bioinformatics, an outstanding project from co-founders Josh Chorlton & Sam Chorlton. 9. Albert Labs, rapidly advancing drug development for mental health disorders. 10. Asep Medical Holdings Inc., established by Robert Hancock, revolutionizing the diagnosis of sepsis. 11. Purpose Life Sciences, aiming to redefine clinical trials globally. These companies are not only revolutionizing biotech, but also making British Columbia a global trending spot in the field. Let's appreciate their amazing work in healthcare, medical advancements, and life science! #Biotechnology #Startups #Innovation #Healthcare #LifeSciences #BCBusiness
Emerging Biotech Startups Thriving in British Columbia, Canada - BestStartup Canada
https://beststartup.ca
-
The future of bioscience innovation is here. Today, we celebrated the official launch of IU Launch Accelerator for Biosciences (IU LAB) at 16 Tech Innovation District in Indianapolis. This first-of-its-kind academic-industry initiative, supported by a $138 million Lilly Endowment Inc. grant, will serve as a dynamic hub, driving collaboration between Indiana University and industry in critical areas of bioscience and health research, establishing Indiana as a global leader in bioscience innovation. We were honored to be joined by Governor Braun, Mayor Hogsett, David Rosenberg (the new president and CEO of IU LAB), Cook Medical President Pete Yonkman, and leaders from the Indiana Biosciences Research Institute, Regenstrief Institute, Inc., Indiana University Health, and Central Indiana Corporate Partnership. Their collaboration will ensure IU LAB thrives as a hub of innovation, driving advancements in healthcare, creating pathways for the next generation of bioscience leaders, and fueling the development of one of our state’s most vital industry sectors. IU LAB’s mission goes beyond research—it is about making a tangible impact on human health and transforming the local community. By fostering academic-industry partnerships, providing educational opportunities, and supporting IU entrepreneurs developing new startup companies, IU LAB will accelerate the commercialization of new biosciences discoveries and help empower local residents with career opportunities. This launch further solidifies Indiana University Indianapolis’ status as a premier urban research institution, amplifying its role as a leader in bioscience innovation and community transformation. It marks a pivotal moment in realizing the ambitious goals of the IU 2030 strategic plan, setting the stage for Indiana to lead in bioscience research and innovation. AcceLINX Adipo Therapeutics Aurorium BioCrossroads Eli Lilly and Company Hoosier Cancer Research Network INCOG BioPharma Services Indiana CTSI myBiometry OrthoWorx, Inc. Plug and Play Tech Center
-
This week we celebrated the official launch of IU Launch Accelerator for Biosciences (IU LAB) at 16 Tech Innovation District in Indianapolis. The remarks from Emily Krueger, President Whitten, Clay Robbins, David Rosenberg, Governor Braun, Mayor Hogsett, and Pete Yonkman demonstrated how leadership catalyzes collaboration. Supported by a $138 million Lilly Endowment Inc. grant, IU LAB will serve as a dynamic hub, driving collaboration between Indiana University and industry in critical areas of bioscience and health research, establishing Indiana as a global leader in bioscience innovation. Collaborative leadership drives progress toward a future we want.
The future of bioscience innovation is here. Today, we celebrated the official launch of IU Launch Accelerator for Biosciences (IU LAB) at 16 Tech Innovation District in Indianapolis. This first-of-its-kind academic-industry initiative, supported by a $138 million Lilly Endowment Inc. grant, will serve as a dynamic hub, driving collaboration between Indiana University and industry in critical areas of bioscience and health research, establishing Indiana as a global leader in bioscience innovation. We were honored to be joined by Governor Braun, Mayor Hogsett, David Rosenberg (the new president and CEO of IU LAB), Cook Medical President Pete Yonkman, and leaders from the Indiana Biosciences Research Institute, Regenstrief Institute, Inc., Indiana University Health, and Central Indiana Corporate Partnership. Their collaboration will ensure IU LAB thrives as a hub of innovation, driving advancements in healthcare, creating pathways for the next generation of bioscience leaders, and fueling the development of one of our state’s most vital industry sectors. IU LAB’s mission goes beyond research—it is about making a tangible impact on human health and transforming the local community. By fostering academic-industry partnerships, providing educational opportunities, and supporting IU entrepreneurs developing new startup companies, IU LAB will accelerate the commercialization of new biosciences discoveries and help empower local residents with career opportunities. This launch further solidifies Indiana University Indianapolis’ status as a premier urban research institution, amplifying its role as a leader in bioscience innovation and community transformation. It marks a pivotal moment in realizing the ambitious goals of the IU 2030 strategic plan, setting the stage for Indiana to lead in bioscience research and innovation. AcceLINX Adipo Therapeutics Aurorium BioCrossroads Eli Lilly and Company Hoosier Cancer Research Network INCOG BioPharma Services Indiana CTSI myBiometry OrthoWorx, Inc. Plug and Play Tech Center
-
A great kickoff to the IU Launch Accelerator for Biosciences (IU LAB) with Indiana University President Pamela Whitten, Lilly Endowment and Pete Yonkman of Cook Medical. The IU LAB is the front door where academia meets industry - driving innovation in human health. The IU LAB will harness IU's nearly $1 billion research enterprise and Indiana's $95 billion life science economy to be the national leader in discovery, commercialization and talent development. Follow our page as we embark on this ambitious initiative, and please reach out to discuss opportunities to collaborate with students, faculty, researchers, entrepreneurs, start-ups and leading industry partners as we drive groundbreaking research and innovation. Let's go change the world together. 16 Tech Innovation District Indiana Biosciences Research Institute Regenstrief Institute, Inc. Indiana University Health Central Indiana Corporate Partnership AcceLINX Adipo Therapeutics Aurorium BioCrossroads Eli Lilly and Company Hoosier Cancer Research Network INCOG BioPharma Services Indiana CTSI myBiometry OrthoWorx, Inc. Plug and Play Tech Center Elevate Ventures Zimmer Biomet Roche Russell Mumper Phaedra Corso Jillian Turner Matt Jaworowski Kurt Fullbeck Susan Brock Williams Vince Wong Dan Peterson
The future of bioscience innovation is here. Today, we celebrated the official launch of IU Launch Accelerator for Biosciences (IU LAB) at 16 Tech Innovation District in Indianapolis. This first-of-its-kind academic-industry initiative, supported by a $138 million Lilly Endowment Inc. grant, will serve as a dynamic hub, driving collaboration between Indiana University and industry in critical areas of bioscience and health research, establishing Indiana as a global leader in bioscience innovation. We were honored to be joined by Governor Braun, Mayor Hogsett, David Rosenberg (the new president and CEO of IU LAB), Cook Medical President Pete Yonkman, and leaders from the Indiana Biosciences Research Institute, Regenstrief Institute, Inc., Indiana University Health, and Central Indiana Corporate Partnership. Their collaboration will ensure IU LAB thrives as a hub of innovation, driving advancements in healthcare, creating pathways for the next generation of bioscience leaders, and fueling the development of one of our state’s most vital industry sectors. IU LAB’s mission goes beyond research—it is about making a tangible impact on human health and transforming the local community. By fostering academic-industry partnerships, providing educational opportunities, and supporting IU entrepreneurs developing new startup companies, IU LAB will accelerate the commercialization of new biosciences discoveries and help empower local residents with career opportunities. This launch further solidifies Indiana University Indianapolis’ status as a premier urban research institution, amplifying its role as a leader in bioscience innovation and community transformation. It marks a pivotal moment in realizing the ambitious goals of the IU 2030 strategic plan, setting the stage for Indiana to lead in bioscience research and innovation. AcceLINX Adipo Therapeutics Aurorium BioCrossroads Eli Lilly and Company Hoosier Cancer Research Network INCOG BioPharma Services Indiana CTSI myBiometry OrthoWorx, Inc. Plug and Play Tech Center
-
The official launch of IU LAB paves the way for unprecedented growth and innovation for the IU Indianapolis community and beyond. Located just minutes from campus, IU LAB will serve as a dynamic hub, driving collaboration between IU and industry in critical areas of bioscience and health research, establishing Indiana as a global leader in bioscience innovation.
The future of bioscience innovation is here. Today, we celebrated the official launch of IU Launch Accelerator for Biosciences (IU LAB) at 16 Tech Innovation District in Indianapolis. This first-of-its-kind academic-industry initiative, supported by a $138 million Lilly Endowment Inc. grant, will serve as a dynamic hub, driving collaboration between Indiana University and industry in critical areas of bioscience and health research, establishing Indiana as a global leader in bioscience innovation. We were honored to be joined by Governor Braun, Mayor Hogsett, David Rosenberg (the new president and CEO of IU LAB), Cook Medical President Pete Yonkman, and leaders from the Indiana Biosciences Research Institute, Regenstrief Institute, Inc., Indiana University Health, and Central Indiana Corporate Partnership. Their collaboration will ensure IU LAB thrives as a hub of innovation, driving advancements in healthcare, creating pathways for the next generation of bioscience leaders, and fueling the development of one of our state’s most vital industry sectors. IU LAB’s mission goes beyond research—it is about making a tangible impact on human health and transforming the local community. By fostering academic-industry partnerships, providing educational opportunities, and supporting IU entrepreneurs developing new startup companies, IU LAB will accelerate the commercialization of new biosciences discoveries and help empower local residents with career opportunities. This launch further solidifies Indiana University Indianapolis’ status as a premier urban research institution, amplifying its role as a leader in bioscience innovation and community transformation. It marks a pivotal moment in realizing the ambitious goals of the IU 2030 strategic plan, setting the stage for Indiana to lead in bioscience research and innovation. AcceLINX Adipo Therapeutics Aurorium BioCrossroads Eli Lilly and Company Hoosier Cancer Research Network INCOG BioPharma Services Indiana CTSI myBiometry OrthoWorx, Inc. Plug and Play Tech Center
-
The IU School of Medicine is proud to partner in the launch of IU LAB, with a strong focus on leading the translation of cutting-edge innovation and research into improved patient outcomes through advanced clinical trials, entrepreneurship, and commercialization.
The future of bioscience innovation is here. Today, we celebrated the official launch of IU Launch Accelerator for Biosciences (IU LAB) at 16 Tech Innovation District in Indianapolis. This first-of-its-kind academic-industry initiative, supported by a $138 million Lilly Endowment Inc. grant, will serve as a dynamic hub, driving collaboration between Indiana University and industry in critical areas of bioscience and health research, establishing Indiana as a global leader in bioscience innovation. We were honored to be joined by Governor Braun, Mayor Hogsett, David Rosenberg (the new president and CEO of IU LAB), Cook Medical President Pete Yonkman, and leaders from the Indiana Biosciences Research Institute, Regenstrief Institute, Inc., Indiana University Health, and Central Indiana Corporate Partnership. Their collaboration will ensure IU LAB thrives as a hub of innovation, driving advancements in healthcare, creating pathways for the next generation of bioscience leaders, and fueling the development of one of our state’s most vital industry sectors. IU LAB’s mission goes beyond research—it is about making a tangible impact on human health and transforming the local community. By fostering academic-industry partnerships, providing educational opportunities, and supporting IU entrepreneurs developing new startup companies, IU LAB will accelerate the commercialization of new biosciences discoveries and help empower local residents with career opportunities. This launch further solidifies Indiana University Indianapolis’ status as a premier urban research institution, amplifying its role as a leader in bioscience innovation and community transformation. It marks a pivotal moment in realizing the ambitious goals of the IU 2030 strategic plan, setting the stage for Indiana to lead in bioscience research and innovation. AcceLINX Adipo Therapeutics Aurorium BioCrossroads Eli Lilly and Company Hoosier Cancer Research Network INCOG BioPharma Services Indiana CTSI myBiometry OrthoWorx, Inc. Plug and Play Tech Center
-
A primer on how docking and virtual screening are used in drug discovery. Once you have a biological target and an idea of how you want to modify that target, the next step is often to find a molecule that hits that target as a starting point for a drug. Docking and virtual screening allow you to model the interaction between molecules and targets computationally, filtering billions of options to an amount testable in lab. Though be warned, the ability of docking and virtual screening to separate true hits from false positives remains limited... https://lnkd.in/dGTX9XU2 #drugDiscovery #molecularBiology #chemistry #computationalChemistry #startups #entrepreneurship
Docking and Virtual Screening in Drug Discovery: Finding the Right Hit | Deep Origin
deeporigin.com
-
We are thrilled to be part of this initiative, designed to further fuel our life sciences #workforce and establish Indiana as a global #biosciences leader. The IU Launch Accelerator for Biosciences (IU LAB) at the 16 Tech Innovation District is a collaborative effort that connects industry with #academia to drive advancements in #healthcare and accelerate the commercialization of innovative therapies. Indiana Biosciences Research Institute Regenstrief Institute, Inc. Eli Lilly and Company Indiana University Indianapolis #indiana #iu #lifesciences
The future of bioscience innovation is here. Today, we celebrated the official launch of IU Launch Accelerator for Biosciences (IU LAB) at 16 Tech Innovation District in Indianapolis. This first-of-its-kind academic-industry initiative, supported by a $138 million Lilly Endowment Inc. grant, will serve as a dynamic hub, driving collaboration between Indiana University and industry in critical areas of bioscience and health research, establishing Indiana as a global leader in bioscience innovation. We were honored to be joined by Governor Braun, Mayor Hogsett, David Rosenberg (the new president and CEO of IU LAB), Cook Medical President Pete Yonkman, and leaders from the Indiana Biosciences Research Institute, Regenstrief Institute, Inc., Indiana University Health, and Central Indiana Corporate Partnership. Their collaboration will ensure IU LAB thrives as a hub of innovation, driving advancements in healthcare, creating pathways for the next generation of bioscience leaders, and fueling the development of one of our state’s most vital industry sectors. IU LAB’s mission goes beyond research—it is about making a tangible impact on human health and transforming the local community. By fostering academic-industry partnerships, providing educational opportunities, and supporting IU entrepreneurs developing new startup companies, IU LAB will accelerate the commercialization of new biosciences discoveries and help empower local residents with career opportunities. This launch further solidifies Indiana University Indianapolis’ status as a premier urban research institution, amplifying its role as a leader in bioscience innovation and community transformation. It marks a pivotal moment in realizing the ambitious goals of the IU 2030 strategic plan, setting the stage for Indiana to lead in bioscience research and innovation. AcceLINX Adipo Therapeutics Aurorium BioCrossroads Eli Lilly and Company Hoosier Cancer Research Network INCOG BioPharma Services Indiana CTSI myBiometry OrthoWorx, Inc. Plug and Play Tech Center
